

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Beuvink, Iwan et al.

U.S. APPLICATION NO: 10/590,406

FILED: October 04, 2006

FOR: P53 WILD-TYPE AS BIOMARKER FOR THE TREATMENT WITH  
MTOR INHIBITORS IN COMBINATION WITH A CYTOTOXIC  
AGENT

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Art Unit: 1634

Examiner: Martinell, James


PETITION FOR EXTENSION OF TIME

Sir:

The Office Action of December 23, 2008 has a shortened statutory time set to expire on March 23, 2009. A three-month extension is hereby requested pursuant to 37 CFR §1.136(a).

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$1110 for payment of the extension fee. The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.17 which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Respectfully submitted,

  
\_\_\_\_\_  
Gregory Doughton  
Attorney for Applicant  
Reg. No. 47,666

Novartis Pharmaceuticals Corporation  
One Health Plaza, Bldg. 101  
East Hanover, NJ 07936  
(862) 778-2614

Date: May 27, 2009